Kolexia
Boisselier Pierre
Oncologie radiothérapie
Icm Montpellier
Montpellier, France
135 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la tête et du cou Tumeurs du poumon Carcinome épidermoïde Carcinomes Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinome épidermoïde de la tête et du cou Tumeurs de l'oropharynx Tumeurs du rhinopharynx

Industries

Merck-Serono
14 collaboration(s)
Dernière en 2023
AstraZeneca
7 collaboration(s)
Dernière en 2023
BMS
4 collaboration(s)
Dernière en 2020
Inter-View Partners France
4 collaboration(s)
Dernière en 2023

Dernières activités

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION): A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Essai Clinique (Emd Serono)   05 mars 2024
Profiles, diagnostic process, and patterns of care of patients with stage III non-small cell lung cancer: A French national study
Respiratory medicine and research   23 janvier 2024
Benefits of artificial nutrition for head and neck cancer patients treated with concomitant chemoradiotherapy
Clinical nutrition ESPEN   01 décembre 2023
PRIMALung: PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   02 novembre 2023
1291O Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): A prospective multicentre, open-label, randomised, controlled trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Stereotactic radiotherapy for operable stage I non-small cell lung cancer.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   08 août 2023
Stereotactic Body Radiation Therapy for less than 3cm (stage I) and 5cm (stage II) inoperable lung tumors: 10 years experience of Montpellier Cancer Institute.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   01 août 2023
Pertinence des recommandations nutrition cancer de la SNFCM dans les cancers de la tête et du cou traités par radiochimiothérapie concomitante (RCT)
Journées Francophones de Nutrition - Livre des résumés 2023   01 mai 2023
Response to Somay et al. Letter to the Editor Regarding "Trismus Occurrence and Link With Radiotherapy Doses in Head and Neck Cancer Patients Treated With Chemoradiotherapy".
Integrative cancer therapies   12 avril 2023
DURVALUNG: A Phase II Study of Durvalumab (MEDI 4736) Maintenance in Frail Limited Disease Small Cell Lung Cancer Patients After Thoracic Chemoradiotherapy (CRT)
Essai Clinique (AstraZeneca)   27 mars 2023